How to Say Mounjaro: Pronunciation, Origin and What the Name Means

Breaking down the syllables: MOWN-JAR-oh

The brand name splits cleanly into three spoken beats. The first syllable rhymes with "own" or "moan", an M sound followed by a long O. The second syllable, where the emphasis lands, is "JAR", exactly as in the kitchen variety. The third is a soft, unstressed "oh". Put those together and you get: mown-JAR-oh.

The most common mistake is placing the stress on the first syllable and saying MOW-un-jaro, or stretching the last syllable into mown-jar-OH as though it rhymes with "pharaoh". Neither is correct. A useful memory trick: think of the sentence "I own a jar" and collapse it, I-OWN-JAR-oh. That stress pattern holds.

Eli Lilly has not published an official etymology for the name, so any explanation of what "Mounjaro" means is speculative. Some observers have noted similarities to Kilimanjaro, but Lilly has not confirmed this. The name was coined as a brand and carries no clinical meaning. What matters in practice is that your prescriber, pharmacist and GP all recognise the word immediately when you use it, and mown-JAR-oh will do exactly that. You can read more about the medicine itself on our Mounjaro medication overview.

How to pronounce tirzepatide, the active ingredient

Once you have Mounjaro down, the active substance comes next. Tirzepatide is the international non-proprietary name, the clinical, non-brand name used in prescriptions, trial papers and regulatory documents. It is pronounced tir-ZEP-a-tide: four syllables, with the stress falling firmly on the second.

Breaking it apart: tir (as in "tire"), ZEP (rhymes with "step", said a little harder), a (a quiet schwa, like the "a" in "about"), and tide (exactly as in the sea). The full word: tir-ZEP-a-tide. The NICE technology appraisal TA1026, which evaluates tirzepatide for weight management in adults, uses this spelling and pronunciation throughout, and when healthcare professionals talk about the class of medicine, it's the name they reach for.

It helps to know that the -tide suffix appears in many peptide-based medicines (liraglutide, semaglutide), so once you've learnt that ending, it stays with you. For a closer look at how this ingredient works in the body, the tirzepatide overview explains the dual-receptor mechanism in plain English. If you want more on the spoken form specifically, we've also written a dedicated page on tirzepatide pronunciation in English.

Why getting the name right can matter in practice

There is a practical side to this that goes beyond confidence in conversation. When you speak to your GP to request a notification, or call a pharmacy to check on a supply, using the right name and spelling prevents confusion with other medicines. Mounjaro and semaglutide (sold as Wegovy for weight management) are sometimes conflated in conversation. Tirzepatide is distinct: it is the only dual GIP and GLP-1 receptor agonist licensed for weight management in the UK, as confirmed by the NHS medicines page for tirzepatide.

There is also a safety dimension. The MHRA has documented cases of counterfeit weight-loss pens circulating in the UK, and mis-spelled or phonetically mangled brand names are sometimes used in fraudulent listings online. Knowing the correct name (and knowing that legitimate supply comes via a GPhC-registered pharmacy following clinical assessment) is a small but real layer of protection. Our page on Mounjaro in the UK covers the supply and safety picture in more detail.

The question of cost is one that comes up alongside all of this. Eli Lilly adjusted Mounjaro's UK list price from September 2025, and private prices have shifted accordingly. For current context, our guide to the Eli Lilly price increase sets out what changed and why. Pricing is never a reason to seek a version of the medicine from an unverified seller. The correct name, correctly spelled, from a registered pharmacy is always the starting point.

From knowing the name to understanding the treatment

Knowing how to say Mounjaro is a small first step; understanding whether the treatment is appropriate for you is the clinical question that follows. Mounjaro (tirzepatide) is licensed in the UK for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, raised cholesterol or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber takes the full picture into account, not just a single number.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the day it's submitted. There is no automated approval. If you'd like to understand how the medicine works before or alongside any consultation, the page on how Mounjaro works covers the mechanism, and our weight-loss treatment overview sets the broader context. When you are ready to take the clinical step, you can speak to our prescribers through a free consultation that includes ID verification, live weight confirmation and clinical review.